Announcement

Medidata, a brand of Dassault Systèmes, announced on July 30, 2026 in Singapore the launch of Medidata Plus, an AI‑native layer built on its award‑winning AI foundation and integrated across the Medidata Platform.

Product Overview

Medidata Plus is described as a unified, end‑to‑end AI strategy that replaces fragmented point solutions. It provides sponsors and contract research organisations (CROs) with portfolio‑wide, outcome‑driven AI capabilities throughout the clinical trial lifecycle, from study build to data management and risk monitoring.

Key capabilities listed:

  • Study Builds Accelerated with AI – automates electronic data capture (EDC) and electronic patient‑reported outcomes (eCOA) design and generates synthetic patient data for user‑acceptance testing, reducing study build timelines from weeks to hours.
  • No‑Code Data Transformation – ingests, standardises and transforms data from clinical and real‑world sources without writing code.
  • Proactive De‑risking – embedded analytics instantly flag enrollment downtrends or safety signals, cutting mid‑cycle pauses and speeding inspections.
  • Companioning Audit Exploration – agentic AI enables natural‑language queries of end‑to‑end audit history, turning regulatory data into actionable insights within minutes.

Market Context

According to the release, 92 % of industry decision‑makers plan to increase AI investment, yet only 29 % say current AI meets or exceeds expectations. Medidata Plus is positioned to address these gaps by standardising the data layer and turning unpredictable AI costs into a predictable investment.

Leadership Quotes

Dr. Nimita Limaye, Research Vice‑President, Life Sciences R&D Strategy and Technology at IDC, said: “Stitching together point solutions isn’t a strategy — it’s a liability. Drug development’s next leap will come when AI is consistent, connected, and portfolio‑wide.”

Anthony Costello, CEO of Medidata, added: “Medidata Plus is a drop‑in AI strategy for clinical research that up‑skills teams, automates workflows, and surfaces insights at a pace that’s redefining what teams thought was possible.”

Scale and Reach

Medidata’s AI infrastructure recently received the highest “Luminary” rating in Everest Group’s AI Innovation Watch Report. The company states its AI supported 80 % of FDA novel drug approvals in 2025. Medidata’s data assets comprise more than 38,000 trials and 12 million patients, serving over 1 million registered users across approximately 2,300 customers worldwide.

Contact and Further Information

For more details, the release directs readers to Medidata’s website and provides PR contact emails (Medidata.PR@3ds.com, Medidata.AR@3ds.com). The announcement was distributed via PRNewswire.